<p>随着全球市场展现出韧性，主要指数显著上涨，受益于地缘政治紧张局势缓解和油价下跌，投资者情绪转向积极。这种环境为发现未被发掘的潜力股提供了肥沃的土壤——那些可能被低估或忽视，但在市场条件改善和乐观情绪恢复的情况下有潜力蓬勃发展的股票。</p>
<h3>全球十大未被发掘的潜力股，基本面强劲</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>精华制药集团</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH 集团</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>汕头超声仪器研究所</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>江苏彩虹重工</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>投资之家</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中业达电气</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>哈马特集团</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>厦门金龙汽车集团</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>武汉华康世纪清洁科技</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus 集团控股</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球未被发掘的潜力股强劲基本面的 3136 只股票的完整列表。</p>
<p>以下是我们筛选出的股票精选。</p>
<h2>合肥埃科光电 (SHSE:688610)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 合肥埃科光电有限公司专注于工业成像、高精度光学和光电设备的设计、开发、制造和营销，市值为 63.3 亿人民币。</p>
<p><strong>运营：</strong> 埃科光电的收入主要来自工业成像、高精度光学和光电设备。公司的净利润率反映了其运营效率和盈利趋势。</p>
<p>合肥埃科光电作为电子行业的灵活参与者，过去一年盈利增长达 306.8%，远超行业平均水平 12.5%。该公司报告 2025 年 12 月的销售额为 4.4031 亿人民币，净收入为 6409 万人民币，反映出强劲的运营表现。尽管近期股价波动较大，合肥埃科的负债权益比在五年内显著改善，从 51.1% 降至仅 2.6%，显示出强健的财务健康状况，为未来在其市场细分中的扩展机会奠定了良好基础。</p>
<ul>
<li>通过阅读我们的健康报告，深入了解合肥埃科光电的表现。</li>
<li>在我们的历史部分探索历史数据，以跟踪合肥埃科光电的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688610 截至 2026 年 4 月的盈利和收入增长</p>
<h2>奥美医疗产品有限公司 (SZSE:002950)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 奥美医疗产品有限公司专注于在中国制造和销售伤口护理和护理材料产品，市值为 83.9 亿人民币。</p>
<p><strong>运营：</strong> 该公司的收入主要来自伤口护理和护理材料产品的销售。</p>
<p>奥美医疗产品有限公司展现出引人注目的图景，过去一年盈利增长达 100.9%，远超行业的温和增长 1.2%。该公司财务状况稳健，现金超过总债务，且在五年内将负债权益比从 40.3% 降至 13%。目前交易价格低于公允价值估算的 17.9%，似乎被市场低估。其高质量的盈利和 103.8 倍的利息覆盖比进一步突显了财务健康，而积极的自由现金流则表明运营效率良好，且对这家有前景的医疗设备制造商没有立即的流动性担忧。</p>
<ul>
<li>在我们的健康报告中更深入地了解奥美医疗产品有限公司的潜力。</li>
<li>通过我们的历史报告获取奥美医疗产品有限公司的过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002950 截至 2026 年 4 月的负债权益比</p>
<h2>江苏聚杰微纤科技集团 (SZSE:300819)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 江苏聚杰微纤科技集团有限公司专注于微纤维材料及相关产品的生产和销售，市值为 69.4 亿人民币。</p>
<p><strong>运营：</strong> 该公司的收入主要来自其纺织和服装业务，产生了 5.652 亿人民币的收入。</p>
<p>聚杰微纤作为纺织行业的灵活参与者，展现出引人注目的财务动态。在过去五年中，其负债权益比从 3% 显著降低至 1.3%，显示出更强的资产负债表。该公司去年盈利增长 1.8%，超出奢侈品行业平均水平 1.5%。随着过去的高质量盈利和截至 2024 年 12 月的 5800 万美元的正自由现金流，尽管近期股价波动，似乎仍然有进一步稳定的潜力。展望未来，预测显示年盈利增长率超过 36%，暗示在这一细分市场中存在潜在的价值创造机会。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解江苏聚杰微纤科技集团的动态。</li>
<li>通过查看我们的历史表现报告，获取江苏聚杰微纤科技集团的历史表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月的 SZSE:300819 债务与股本比率</p>
<h2>让它发生</h2>
<ul>
<li>解锁更多宝藏！我们的全球未被发现的强基本面宝藏筛选器为您挖掘了 3133 家更多公司供您探索。点击这里揭开我们精心策划的 3136 家全球未被发现的强基本面宝藏的名单。</li>
<li>这些公司中有哪一些是您资产组合的一部分吗？利用 Simply Wall St 的投资组合分析能力，全面了解它们的表现。</li>
<li>利用 Simply Wall St 的力量进行明智投资，这是您在全球股市中导航的免费指南。</li>
</ul>
<h2>准备好不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

埃科光电

奥美医疗

聚杰微纤

精华制药

<p>随着全球市场展现出韧性并取得显著收益，投资者情绪转向积极，为识别被低估的股票创造了机会。报告强调了 10 个未被发现的优质股票，这些公司具有强大的基本面，包括精华制药集团和合肥埃科光电，它们展现了令人印象深刻的盈利增长和改善的财务健康状况。像奥美医疗和江苏聚杰微纤科技集团这样的公司也表现出强劲的运营业绩和未来增长的潜力。整体环境对在股市中发现有前景的投资机会是有利的</p>

<p>As global markets show resilience with notable gains in major indices, buoyed by easing geopolitical tensions and a decline in oil prices, investor sentiment has shifted positively. This environment provides a fertile ground for identifying undiscovered gems—stocks that may be undervalued or overlooked but have the potential to thrive amid improving market conditions and renewed optimism.</p>
<div class="lb-trans"><p>随着全球市场展现出韧性，主要指数显著上涨，受益于地缘政治紧张局势缓解和油价下跌，投资者情绪转向积极。这种环境为发现未被发掘的潜力股提供了肥沃的土壤——那些可能被低估或忽视，但在市场条件改善和乐观情绪恢复的情况下有潜力蓬勃发展的股票。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被发掘的潜力股，基本面强劲</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jinghua Pharmaceutical Group</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH Group</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shantou Institute of Ultrasonic Instrument</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Jiangsu Rainbow Heavy Industries</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>House of Investments</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zhongyeda Electric</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hamat Group</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Xiamen King Long Motor Group</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wuhan Huakang Century Clean Technology</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus Group Holdings</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>精华制药集团</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH 集团</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>汕头超声仪器研究所</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>江苏彩虹重工</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>投资之家</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中业达电气</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>哈马特集团</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>厦门金龙汽车集团</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>武汉华康世纪清洁科技</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus 集团控股</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3136 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球未被发掘的潜力股强劲基本面的 3136 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>以下是我们筛选出的股票精选。</p>
</div><h2>Hefei I-TEK OptoElectronics (SHSE:688610)</h2>
<div class="lb-trans"><h2>合肥埃科光电 (SHSE:688610)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Hefei I-TEK OptoElectronics Co., Ltd. is engaged in the design, development, manufacturing, and marketing of industrial imaging, high precision optics, and opto-electrical equipment in China with a market cap of CN¥6.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 合肥埃科光电有限公司专注于工业成像、高精度光学和光电设备的设计、开发、制造和营销，市值为 63.3 亿人民币。</p>
</div><p><strong>Operations:</strong> I-TEK OptoElectronics generates revenue primarily from industrial imaging, high precision optics, and opto-electrical equipment. The company's net profit margin reflects its operational efficiency and profitability trends over time.</p>
<div class="lb-trans"><p><strong>运营：</strong> 埃科光电的收入主要来自工业成像、高精度光学和光电设备。公司的净利润率反映了其运营效率和盈利趋势。</p>
</div><p>Hefei I-TEK OptoElectronics, a nimble player in the electronics sector, has demonstrated impressive growth with earnings surging by 306.8% over the past year, outpacing the industry average of 12.5%. The company reported sales of CNY 440.31 million and net income of CNY 64.09 million for the year ending December 2025, reflecting strong operational performance. Despite its volatile share price recently, Hefei I-TEK's debt to equity ratio has significantly improved from 51.1% to just 2.6% over five years, indicating robust financial health and positioning it well for future expansion opportunities in its market segment.</p>
<div class="lb-trans"><p>合肥埃科光电作为电子行业的灵活参与者，过去一年盈利增长达 306.8%，远超行业平均水平 12.5%。该公司报告 2025 年 12 月的销售额为 4.4031 亿人民币，净收入为 6409 万人民币，反映出强劲的运营表现。尽管近期股价波动较大，合肥埃科的负债权益比在五年内显著改善，从 51.1% 降至仅 2.6%，显示出强健的财务健康状况，为未来在其市场细分中的扩展机会奠定了良好基础。</p>
</div><ul>
<li>Get an in-depth perspective on Hefei I-TEK OptoElectronics' performance by reading our health report here.</li>
<li>Explore historical data to track Hefei I-TEK OptoElectronics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的健康报告，深入了解合肥埃科光电的表现。</li>
<li>在我们的历史部分探索历史数据，以跟踪合肥埃科光电的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688610 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>SHSE:688610 截至 2026 年 4 月的盈利和收入增长</p>
</div><h2>Allmed Medical ProductsLtd (SZSE:002950)</h2>
<div class="lb-trans"><h2>奥美医疗产品有限公司 (SZSE:002950)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Allmed Medical Products Co., Ltd specializes in the manufacturing and sale of wound care and nursing material products within China, with a market capitalization of CN¥8.39 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 奥美医疗产品有限公司专注于在中国制造和销售伤口护理和护理材料产品，市值为 83.9 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the sale of wound care and nursing material products.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自伤口护理和护理材料产品的销售。</p>
</div><p>Allmed Medical Products Ltd. paints an intriguing picture with its impressive earnings growth of 100.9% in the past year, outpacing the industry's modest 1.2%. The company appears financially robust, boasting more cash than total debt and reducing its debt-to-equity ratio from 40.3% to 13% over five years. Trading at a discount of 17.9% below fair value estimates, it seems undervalued by market standards. Its high-quality earnings and strong interest coverage ratio of 103.8x EBIT further highlight financial health, while positive free cash flow indicates operational efficiency without immediate liquidity concerns for this promising player in medical equipment manufacturing.</p>
<div class="lb-trans"><p>奥美医疗产品有限公司展现出引人注目的图景，过去一年盈利增长达 100.9%，远超行业的温和增长 1.2%。该公司财务状况稳健，现金超过总债务，且在五年内将负债权益比从 40.3% 降至 13%。目前交易价格低于公允价值估算的 17.9%，似乎被市场低估。其高质量的盈利和 103.8 倍的利息覆盖比进一步突显了财务健康，而积极的自由现金流则表明运营效率良好，且对这家有前景的医疗设备制造商没有立即的流动性担忧。</p>
</div><ul>
<li>Take a closer look at Allmed Medical ProductsLtd's potential here in our health report.</li>
<li>Gain insights into Allmed Medical ProductsLtd's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解奥美医疗产品有限公司的潜力。</li>
<li>通过我们的历史报告获取奥美医疗产品有限公司的过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002950 Debt to Equity as at Apr 2026</p>
<div class="lb-trans"><p>SZSE:002950 截至 2026 年 4 月的负债权益比</p>
</div><h2>Jiangsu Jujie Microfiber Technology Group (SZSE:300819)</h2>
<div class="lb-trans"><h2>江苏聚杰微纤科技集团 (SZSE:300819)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Jiangsu Jujie Microfiber Technology Group Co., Ltd. focuses on the production and sale of microfiber materials and related products, with a market cap of CN¥6.94 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 江苏聚杰微纤科技集团有限公司专注于微纤维材料及相关产品的生产和销售，市值为 69.4 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Textile and Clothing Business, which generated CN¥565.20 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自其纺织和服装业务，产生了 5.652 亿人民币的收入。</p>
</div><p>Jujie Microfiber, a nimble player in the textile sector, showcases intriguing financial dynamics. Over the past five years, its debt to equity ratio has impressively reduced from 3% to 1.3%, indicating a stronger balance sheet. The company's earnings growth of 1.8% last year outpaced the Luxury industry average of 1.5%. With high-quality past earnings and free cash flow turning positive recently at US$58 million as of December 2024, it seems poised for further stability despite recent share price volatility. Looking ahead, forecasts suggest an annual earnings growth rate of over 36%, hinting at potential value creation opportunities in this niche market segment.</p>
<div class="lb-trans"><p>聚杰微纤作为纺织行业的灵活参与者，展现出引人注目的财务动态。在过去五年中，其负债权益比从 3% 显著降低至 1.3%，显示出更强的资产负债表。该公司去年盈利增长 1.8%，超出奢侈品行业平均水平 1.5%。随着过去的高质量盈利和截至 2024 年 12 月的 5800 万美元的正自由现金流，尽管近期股价波动，似乎仍然有进一步稳定的潜力。展望未来，预测显示年盈利增长率超过 36%，暗示在这一细分市场中存在潜在的价值创造机会。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Jiangsu Jujie Microfiber Technology Group.</li>
<li>Gain insights into Jiangsu Jujie Microfiber Technology Group's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解江苏聚杰微纤科技集团的动态。</li>
<li>通过查看我们的历史表现报告，获取江苏聚杰微纤科技集团的历史表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis"/></p>
<p>SZSE:300819 Debt to Equity as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SZSE:300819 债务与股本比率</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Unlock more gems! Our Global Undiscovered Gems With Strong Fundamentals screener has unearthed 3133 more companies for you to explore.Click here to unveil our expertly curated list of 3136 Global Undiscovered Gems With Strong Fundamentals.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的全球未被发现的强基本面宝藏筛选器为您挖掘了 3133 家更多公司供您探索。点击这里揭开我们精心策划的 3136 家全球未被发现的强基本面宝藏的名单。</li>
<li>这些公司中有哪一些是您资产组合的一部分吗？利用 Simply Wall St 的投资组合分析能力，全面了解它们的表现。</li>
<li>利用 Simply Wall St 的力量进行明智投资，这是您在全球股市中导航的免费指南。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

在 2026 年 4 月发掘全球尚未被发现的宝石